- ClinicalTrials.gov ID: NCT02582697
- Recruiting participants (Starts Sep. 4, 2018)
- Not accepting healthy volunteers
- UTSW Principal Investigator: JONATHAN ERIC WICKISER
summary
This trial is an open label, randomized, stratified 2-arm australian-led multicenter phase 3 clinical trial undertaken in two stages. Participants will be randomized via a central system administered by the australian nHMRC Clinical Trials Centre into either a "standard BeP" group or "accelerated BeP" group. Participants will be assigned to the two treatment arms in a 1:1 ratio and evaluated weekly, and then for 5 years after completing the study to assess the long-term effects of the chemotherapy.
objective
To determine if accelerated BeP (Bleomycin, etoposide, cisPlatin) is superior to standard BeP as first-line chemotherapy for intermediate and poor-risk metastatic GCTs